GlassScriptPhysician profile
Christopher P Nguyen
NPI 1588624100
$4,194.66
in general payments reported to CMS, 2019-2025
34 companies · $664 in 2025
The $664 reported for 2025 was more than what 83% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2021: $100 · 2022: $1,247 · 2023: $572 · 2024: $1,145 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,081.41 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.02 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $418.88 | 2022-2025 | |
| Amgen INC. | $327.93 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $269.28 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $213.47 | 2019-2023 | |
| Dexcom, INC. | $153.50 | 2022-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $146.61 | 2019 | |
| Janssen Biotech, INC. | $127.71 | 2022-2024 | Tremfya |
| Merck Sharp & Dohme LLC | $106.74 | 2019-2025 | Capvaxive |
| Exact Sciences Corporation | $93.47 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $92.28 | 2022-2023 | Breztri |
| Ucb, INC. | $46.59 | 2025 | Bimzelx |
| Novo Nordisk INC | $44.27 | 2022 | |
| Tandem Diabetes Care, INC. | $44.16 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $40.74 | 2022 | |
| Beta Bionics, INC. | $35.94 | 2024 | Ilet Bionic Pancreas |
| Idorsia Pharmaceuticals US INC | $34.56 | 2022-2023 | Quviviq |
| Pfizer INC. | $33.06 | 2024 | |
| Astellas Pharma US INC | $31.26 | 2019 | |
| Abbvie INC. | $31.05 | 2022 | |
| Neotract INC. | $26.73 | 2019 | |
| Cequr Corporation | $25.58 | 2022-2023 | Cequr Simplicity |
| Glaxosmithkline, LLC. | $22.82 | 2022 | |
| Inspire Medical Systems, INC. | $22.42 | 2024 | Inspire |
| Ipsen Biopharmaceuticals, INC | $21.20 | 2024 | Bylvay |
| Neurelis, INC. | $19.62 | 2021 | |
| Medtronic USA, INC. | $18.04 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.61 | 2022 | |
| Sk Life Science, INC. | $17.60 | 2021 | |
| Circassia INC. | $15.43 | 2019 | |
| Cranial Technologies, INC | $12.98 | 2022 | |
| Acerus Pharmaceuticals Corporation | $12.76 | 2022 | |
| Boston Scientific Corporation | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.